PRESS RELEASE ABBOTT PARK, Ill ., April 14, 2015 /PRNewswire/ – – Today, Abbott and Sekisui announce an agreement to offer coagulation tests solutions for laboratories worldwide. Coagulation testing measure a person's blood clotting ability, that may help doctors assess risks of excessive bleeding or developing clots. Beneath the agreement, Abbott would be the exclusive distributor of Sekisui's new CP3000 coagulation instrument in the usa, European countries and other regions that recognize CE Mark. Abbott is focused on providing testing solutions that healthcare providers rely on for actionable info in diagnosing and dealing with various medical conditions, stated Jaime Contreras, senior vice president, Commercial Functions, Diagnostics, Abbott.

Phase 2 research of atrasentan in this patient population show encouraging results, and we look forward to further evaluating this investigational treatment in the Phase 3 SONAR study. Diabetic nephropathy, or diabetic kidney disease, can be a common complication of diabetes and the leading reason behind CKD in the developed world. We are committed to enhancing renal outcomes for sufferers with type 2 diabetes, where there is certainly significant unmet need, said James Stolzenbach, Ph.D., divisional vice president, renal and dyslipidemia, AbbVie.